{"hands_on_practices": [{"introduction": "This first practice goes back to fundamentals, exploring one of the most significant age-related pharmacokinetic changes: reduced drug clearance. By working from the basic principles of mass balance, you will quantitatively derive how a decrease in clearance ($CL$) directly lengthens a drug's elimination half-life ($t_{1/2}$) and increases its steady-state concentration ($C_{ss}$). This exercise provides the foundational understanding for why dosage adjustments are a cornerstone of safe prescribing in older adults [@problem_id:4953364].", "problem": "An older adult undergoes a change in physiology consistent with aging, resulting in a reduction in drug clearance. Consider a drug administered by continuous intravenous (IV) infusion into a patient whose pharmacokinetics are well described by a one-compartment model with first-order elimination. Let $A(t)$ denote the amount of drug in the body at time $t$, $C(t)$ the plasma concentration, $V_{d}$ the apparent volume of distribution, $\\mathrm{CL}$ the clearance, and $R_{\\mathrm{in}}$ the constant infusion rate. Clearance is defined as the proportionality factor linking the elimination rate to concentration, so that the elimination rate is $\\mathrm{CL}\\,C(t)$, and $C(t) = A(t)/V_{d}$. Assume baseline parameters $\\mathrm{CL}_{0}$ and $V_{d}$, and that the infusion rate $R_{\\mathrm{in}}$ is held constant.\n\nStarting from mass balance and the definitions given, derive expressions for the elimination half-life $t_{1/2}$ (the time required for $A(t)$ to decrease to one-half of its initial value after infusion is stopped) and the steady-state concentration $C_{ss}$ under constant infusion. Then, model a geriatric change in which clearance decreases by $25\\%$ to $\\mathrm{CL}_{\\text{new}} = 0.75\\,\\mathrm{CL}_{0}$ while $V_{d}$ and $R_{\\mathrm{in}}$ remain unchanged. Compute the multiplicative factors by which $t_{1/2}$ and $C_{ss}$ change relative to their baseline values, expressed as exact fractions. Provide your final answer as a row matrix containing the factor for $t_{1/2}$ followed by the factor for $C_{ss}$.", "solution": "The problem statement is scientifically grounded, well-posed, objective, and contains all necessary information to derive a unique solution. It is a standard exercise in pharmacokinetic modeling, based on fundamental principles of mass balance and first-order kinetics. The scenario of reduced clearance in a geriatric patient is a well-established concept in clinical pharmacology. Therefore, the problem is valid.\n\nWe begin by establishing the governing differential equation for the amount of drug in the body, $A(t)$, based on the principle of mass balance. The rate of change of the amount of drug is the rate of infusion minus the rate of elimination.\n$$\n\\frac{dA(t)}{dt} = (\\text{Rate in}) - (\\text{Rate out})\n$$\nThe rate in is the constant infusion rate, $R_{\\mathrm{in}}$. The rate out is the elimination rate, which is given as $\\mathrm{CL}\\,C(t)$. We are also given the relationship between concentration $C(t)$, amount $A(t)$, and the apparent volume of distribution $V_d$: $C(t) = A(t)/V_d$. Substituting this into the elimination rate expression, we find the rate out is $\\mathrm{CL} \\frac{A(t)}{V_d}$.\n\nThus, the differential equation describing the system during infusion is:\n$$\n\\frac{dA(t)}{dt} = R_{\\mathrm{in}} - \\frac{\\mathrm{CL}}{V_{d}} A(t)\n$$\nIt is conventional to define the first-order elimination rate constant, $k_e$, as the ratio of clearance to volume of distribution:\n$$\nk_e = \\frac{\\mathrm{CL}}{V_{d}}\n$$\nWith this definition, the differential equation becomes:\n$$\n\\frac{dA(t)}{dt} = R_{\\mathrm{in}} - k_e A(t)\n$$\n\nFirst, we derive the expression for the steady-state concentration, $C_{ss}$. At steady state, the amount of drug in the body is constant, which implies that its rate of change is zero, $\\frac{dA(t)}{dt} = 0$. Let $A_{ss}$ be the steady-state amount of drug. Setting the derivative to zero in the mass balance equation gives:\n$$\n0 = R_{\\mathrm{in}} - k_e A_{ss}\n$$\nSolving for $A_{ss}$:\n$$\nA_{ss} = \\frac{R_{\\mathrm{in}}}{k_e}\n$$\nSubstituting $k_e = \\frac{\\mathrm{CL}}{V_{d}}$ back into the expression for $A_{ss}$:\n$$\nA_{ss} = \\frac{R_{\\mathrm{in}}}{\\left(\\frac{\\mathrm{CL}}{V_{d}}\\right)} = \\frac{R_{\\mathrm{in}} V_{d}}{\\mathrm{CL}}\n$$\nThe steady-state concentration, $C_{ss}$, is defined as $C_{ss} = A_{ss} / V_d$. Therefore:\n$$\nC_{ss} = \\frac{1}{V_{d}} \\left( \\frac{R_{\\mathrm{in}} V_{d}}{\\mathrm{CL}} \\right) = \\frac{R_{\\mathrm{in}}}{\\mathrm{CL}}\n$$\nThis is the general expression for steady-state concentration. For the baseline case, we use the baseline clearance, $\\mathrm{CL}_{0}$:\n$$\nC_{ss,0} = \\frac{R_{\\mathrm{in}}}{\\mathrm{CL}_{0}}\n$$\n\nNext, we derive the expression for the elimination half-life, $t_{1/2}$. The half-life is determined after the infusion is stopped. At this point, the rate of infusion $R_{\\mathrm{in}}$ becomes zero, and the differential equation simplifies to describe only the elimination process:\n$$\n\\frac{dA(t)}{dt} = -k_e A(t)\n$$\nThis is a first-order linear homogeneous differential equation. Its solution describes exponential decay:\n$$\nA(t) = A_0 \\exp(-k_e t)\n$$\nwhere $A_0$ is the amount of drug in the body at the time the infusion is stopped (i.e., at $t=0$ for the elimination phase). The half-life, $t_{1/2}$, is the time required for the amount of drug to decrease to one-half of its initial value, i.e., $A(t_{1/2}) = \\frac{1}{2} A_0$.\n$$\n\\frac{1}{2} A_0 = A_0 \\exp(-k_e t_{1/2})\n$$\n$$\n\\frac{1}{2} = \\exp(-k_e t_{1/2})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k_e t_{1/2}\n$$\nUsing the property $\\ln(1/x) = -\\ln(x)$:\n$$\n-\\ln(2) = -k_e t_{1/2}\n$$\nSolving for $t_{1/2}$:\n$$\nt_{1/2} = \\frac{\\ln(2)}{k_e}\n$$\nSubstituting back the definition $k_e = \\frac{\\mathrm{CL}}{V_{d}}$:\n$$\nt_{1/2} = \\frac{\\ln(2) V_{d}}{\\mathrm{CL}}\n$$\nFor the baseline case, using the baseline clearance, $\\mathrm{CL}_{0}$:\n$$\nt_{1/2, 0} = \\frac{\\ln(2) V_{d}}{\\mathrm{CL}_{0}}\n$$\n\nNow, we analyze the effect of the geriatric change. The clearance decreases by $25\\%$, so the new clearance, $\\mathrm{CL}_{\\text{new}}$, is $75\\%$ of the baseline clearance:\n$$\n\\mathrm{CL}_{\\text{new}} = (1 - 0.25)\\,\\mathrm{CL}_{0} = 0.75\\,\\mathrm{CL}_{0} = \\frac{3}{4}\\,\\mathrm{CL}_{0}\n$$\nThe volume of distribution, $V_d$, and the infusion rate, $R_{\\mathrm{in}}$, remain unchanged.\n\nWe compute the new half-life, $t_{1/2, \\text{new}}$:\n$$\nt_{1/2, \\text{new}} = \\frac{\\ln(2) V_{d}}{\\mathrm{CL}_{\\text{new}}} = \\frac{\\ln(2) V_{d}}{\\frac{3}{4}\\,\\mathrm{CL}_{0}} = \\frac{4}{3} \\left( \\frac{\\ln(2) V_{d}}{\\mathrm{CL}_{0}} \\right) = \\frac{4}{3}\\,t_{1/2, 0}\n$$\nThe multiplicative factor by which $t_{1/2}$ changes is the ratio $\\frac{t_{1/2, \\text{new}}}{t_{1/2, 0}}$:\n$$\n\\text{Factor for } t_{1/2} = \\frac{\\frac{4}{3}\\,t_{1/2, 0}}{t_{1/2, 0}} = \\frac{4}{3}\n$$\n\nNext, we compute the new steady-state concentration, $C_{ss, \\text{new}}$:\n$$\nC_{ss, \\text{new}} = \\frac{R_{\\mathrm{in}}}{\\mathrm{CL}_{\\text{new}}} = \\frac{R_{\\mathrm{in}}}{\\frac{3}{4}\\,\\mathrm{CL}_{0}} = \\frac{4}{3} \\left( \\frac{R_{\\mathrm{in}}}{\\mathrm{CL}_{0}} \\right) = \\frac{4}{3}\\,C_{ss, 0}\n$$\nThe multiplicative factor by which $C_{ss}$ changes is the ratio $\\frac{C_{ss, \\text{new}}}{C_{ss, 0}}$:\n$$\n\\text{Factor for } C_{ss} = \\frac{\\frac{4}{3}\\,C_{ss, 0}}{C_{ss, 0}} = \\frac{4}{3}\n$$\n\nThe results indicate that a $25\\%$ decrease in clearance leads to an increase in both half-life and steady-state concentration by a factor of $\\frac{4}{3}$. This is a clinically significant finding: a slower clearance causes the drug to be eliminated more slowly (longer half-life) and to accumulate to higher levels in the body (higher steady-state concentration), which increases the risk of toxicity in geriatric patients if the dose is not adjusted.\n\nThe final answer is a row matrix containing the factor for $t_{1/2}$ followed by the factor for $C_{ss}$. Both factors are $\\frac{4}{3}$.", "answer": "$$\n\\boxed{\\begin{pmatrix} \\frac{4}{3} & \\frac{4}{3} \\end{pmatrix}}\n$$", "id": "4953364"}, {"introduction": "Building on the importance of clearance, this practice addresses a critical clinical challenge: how do we reliably estimate renal function in older adults? This exercise demonstrates the limitations of standard formulas, such as the Cockcroft-Gault equation, particularly in patients with age-related muscle loss (sarcopenia). You will see firsthand how a deceptively normal serum creatinine level can mask significant renal impairment, underscoring the importance of a nuanced, physiologically-informed approach to dosing renally cleared drugs [@problem_id:4953321].", "problem": "An $83$-year-old female with frailty and clinically evident sarcopenia presents for dose adjustment of a renally cleared maintenance drug. Body composition assessment by bioimpedance indicates skeletal muscle mass $M = 13$ kilograms. Her actual body weight is $70$ kilograms, height is $160$ centimeters, and measured Serum Creatinine (SCr) is $0.50$ $\\mathrm{mg}/\\mathrm{dL}$. Assume steady state for creatinine, with production equaling excretion, and adopt the following well-tested approximation: creatinine generation is proportional to skeletal muscle mass, with proportionality constant $k = 40$ $\\mathrm{mg}\\,\\mathrm{kg}^{-1}\\,\\mathrm{day}^{-1}$ (interpreted as an average daily creatine-to-creatinine conversion per kilogram of muscle). Use Actual Body Weight in the Cockcroft–Gault (CG) equation and apply the standard female sex factor.\n\nStarting from the mass balance principle at steady state for creatinine, and using scientifically sound unit conversions (including $\\mathrm{dL}$ to $\\mathrm{mL}$), compute the following in sequence: the creatinine generation rate, the true Creatinine Clearance (CrCl) implied by the mass balance, and the Cockcroft–Gault estimate. Then, adjust the maintenance dose of a hypothetical drug, Renacline, which is cleared $100$ percent by the kidneys. Renacline’s label specifies a reference maintenance regimen of $400$ $\\mathrm{mg}$ every $12$ hours at a reference creatinine clearance of $100$ $\\mathrm{mL}/\\mathrm{min}$, and states that the maintenance dose should scale linearly with the patient’s true creatinine clearance relative to this reference.\n\nDemonstrate the direction of bias introduced by sarcopenia when using Cockcroft–Gault, but report only the final adjusted maintenance dose for Renacline. Express the final dose in $\\mathrm{mg}$ and round your answer to three significant figures.", "solution": "The problem statement first undergoes a rigorous validation process.\n\n### Step 1: Extract Givens\n- Age: $83$ years\n- Sex: Female\n- Condition: Frailty, sarcopenia\n- Skeletal muscle mass ($M$): $13$ kilograms\n- Actual body weight (ABW): $70$ kilograms\n- Height: $160$ centimeters\n- Serum Creatinine (SCr): $0.50$ $\\mathrm{mg}/\\mathrm{dL}$\n- State: Steady state for creatinine (production = excretion)\n- Approximation: Creatinine generation is proportional to skeletal muscle mass.\n- Proportionality constant ($k$): $40$ $\\mathrm{mg}\\,\\mathrm{kg}^{-1}\\,\\mathrm{day}^{-1}$\n- Cockcroft–Gault (CG) instruction: Use Actual Body Weight.\n- CG female sex factor: Apply the standard female sex factor.\n- Drug: Renacline\n- Drug clearance mechanism: $100$ percent by the kidneys.\n- Reference regimen: $400$ $\\mathrm{mg}$ every $12$ hours.\n- Reference creatinine clearance (CrCl): $100$ $\\mathrm{mL}/\\mathrm{min}$.\n- Dosing rule: Maintenance dose scales linearly with the patient’s true creatinine clearance relative to the reference.\n- Final answer requirement: Report the final adjusted maintenance dose in $\\mathrm{mg}$, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded in the principles of pharmacokinetics and renal physiology. The core of the problem rests on the mass balance of creatinine, a well-established concept. The premise that creatinine generation is proportional to muscle mass is a valid physiological approximation. The Cockcroft–Gault equation is a standard clinical tool, and highlighting its limitations in specific populations (like the sarcopenic elderly) is a relevant and important clinical concept. All provided values are physiologically plausible for the described patient. The problem is self-contained, with all necessary data provided for a unique solution. The language is objective and precise.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically sound, well-posed, objective, and formalizable. A detailed solution will be provided.\n\n***\n\nThe solution proceeds by following the sequence of calculations as requested.\n\n**1. Creatinine Generation Rate**\n\nThe rate of creatinine generation ($G_{Cr}$) is given as proportional to the skeletal muscle mass ($M$) with a proportionality constant $k$.\n$$G_{Cr} = M \\times k$$\nSubstituting the given values:\n$$G_{Cr} = 13 \\, \\mathrm{kg} \\times 40 \\, \\frac{\\mathrm{mg}}{\\mathrm{kg} \\cdot \\mathrm{day}} = 520 \\, \\frac{\\mathrm{mg}}{\\mathrm{day}}$$\n\n**2. True Creatinine Clearance (CrCl) from Mass Balance**\n\nAt steady state, the rate of creatinine generation equals the rate of creatinine excretion ($E_{Cr}$). The renal excretion rate is the product of the creatinine clearance ($CrCl$) and the serum creatinine concentration ($SCr$).\n$$G_{Cr} = E_{Cr} = CrCl_{true} \\times SCr$$\nTo solve for $CrCl_{true}$, we must ensure all units are consistent. We will convert all units to minutes ($min$), milliliters ($mL$), and milligrams ($mg$).\n\nFirst, convert the generation rate $G_{Cr}$ from $\\mathrm{mg}/\\mathrm{day}$ to $\\mathrm{mg}/\\mathrm{min}$:\n$$G_{Cr} = 520 \\, \\frac{\\mathrm{mg}}{\\mathrm{day}} \\times \\frac{1 \\, \\mathrm{day}}{24 \\, \\mathrm{hours}} \\times \\frac{1 \\, \\mathrm{hour}}{60 \\, \\mathrm{min}} = \\frac{520}{1440} \\, \\frac{\\mathrm{mg}}{\\mathrm{min}} = \\frac{13}{36} \\, \\frac{\\mathrm{mg}}{\\mathrm{min}}$$\nNext, convert the serum creatinine concentration $SCr$ from $\\mathrm{mg}/\\mathrm{dL}$ to $\\mathrm{mg}/\\mathrm{mL}$:\n$$SCr = 0.50 \\, \\frac{\\mathrm{mg}}{\\mathrm{dL}} \\times \\frac{1 \\, \\mathrm{dL}}{100 \\, \\mathrm{mL}} = 0.0050 \\, \\frac{\\mathrm{mg}}{\\mathrm{mL}} = \\frac{1}{200} \\, \\frac{\\mathrm{mg}}{\\mathrm{mL}}$$\nNow, we can calculate the true creatinine clearance, $CrCl_{true}$:\n$$CrCl_{true} = \\frac{G_{Cr}}{SCr} = \\frac{\\frac{13}{36} \\, \\frac{\\mathrm{mg}}{\\mathrm{min}}}{\\frac{1}{200} \\, \\frac{\\mathrm{mg}}{\\mathrm{mL}}} = \\frac{13}{36} \\times 200 \\, \\frac{\\mathrm{mL}}{\\mathrm{min}} = \\frac{2600}{36} \\, \\frac{\\mathrm{mL}}{\\mathrm{min}} = \\frac{650}{9} \\, \\frac{\\mathrm{mL}}{\\mathrm{min}}$$\nNumerically, $CrCl_{true} \\approx 72.22 \\, \\mathrm{mL}/\\mathrm{min}$.\n\n**3. Cockcroft–Gault (CG) Estimated Creatinine Clearance**\n\nThe Cockcroft–Gault equation for estimating $CrCl$ is:\n$$CrCl_{CG} = \\frac{(140 - \\text{Age}) \\times \\text{Weight in kg}}{72 \\times SCr \\text{ in mg/dL}} \\times (\\text{0.85 if female})$$\nUsing the patient's data:\n- Age = $83$ years\n- Weight (ABW) = $70$ kg\n- $SCr$ = $0.50$ mg/dL\n- Sex = Female (factor of $0.85$ applies)\n$$CrCl_{CG} = \\frac{(140 - 83) \\times 70}{72 \\times 0.50} \\times 0.85$$\n$$CrCl_{CG} = \\frac{57 \\times 70}{36} \\times 0.85 = \\frac{3990}{36} \\times 0.85 \\approx 110.833 \\times 0.85 \\approx 94.208 \\, \\frac{\\mathrm{mL}}{\\mathrm{min}}$$\n\n**Demonstration of Bias**\n\nComparing the two values for creatinine clearance:\n- True CrCl from mass balance: $CrCl_{true} = \\frac{650}{9} \\approx 72.2 \\, \\mathrm{mL}/\\mathrm{min}$\n- Estimated CrCl from CG formula: $CrCl_{CG} \\approx 94.2 \\, \\mathrm{mL}/\\mathrm{min}$\n\nThe Cockcroft–Gault formula significantly overestimates the patient's renal function. This bias occurs because the formula interprets the low serum creatinine ($SCr = 0.50 \\, \\mathrm{mg}/\\mathrm{dL}$) as a sign of excellent kidney function. In reality, the low $SCr$ is a result of reduced creatinine production from a diminished muscle mass (sarcopenia), thus masking the true, moderately reduced renal function. Using the CG estimate would lead to a significant overdose of a renally cleared drug.\n\n**4. Adjusted Maintenance Dose of Renacline**\n\nThe problem states that the maintenance dose should scale linearly with the patient's true creatinine clearance relative to a reference. This can be expressed as:\n$$\\frac{D_{adj}}{CrCl_{true}} = \\frac{D_{ref}}{CrCl_{ref}}$$\nwhere $D$ is the dose per administration, assuming a constant dosing interval. The dose adjustment is therefore:\n$$D_{adj} = D_{ref} \\times \\frac{CrCl_{true}}{CrCl_{ref}}$$\nThe given values are:\n- Reference dose, $D_{ref} = 400$ mg\n- Patient's true clearance, $CrCl_{true} = \\frac{650}{9} \\, \\mathrm{mL}/\\mathrm{min}$\n- Reference clearance, $CrCl_{ref} = 100 \\, \\mathrm{mL}/\\mathrm{min}$\n\nSubstituting these values into the equation:\n$$D_{adj} = 400 \\, \\mathrm{mg} \\times \\frac{\\frac{650}{9} \\, \\mathrm{mL}/\\mathrm{min}}{100 \\, \\mathrm{mL}/\\mathrm{min}} = 400 \\times \\frac{650}{900} = 400 \\times \\frac{65}{90} = 400 \\times \\frac{13}{18}$$\n$$D_{adj} = \\frac{400 \\times 13}{18} = \\frac{200 \\times 13}{9} = \\frac{2600}{9} \\, \\mathrm{mg}$$\nThe numerical value is $D_{adj} \\approx 288.888... \\, \\mathrm{mg}$.\nRounding to three significant figures as required gives $289 \\, \\mathrm{mg}$.\nThe final adjusted maintenance dose for Renacline is $289 \\, \\mathrm{mg}$.", "answer": "$$\\boxed{289}$$", "id": "4953321"}, {"introduction": "Our final practice delves into a more advanced topic: the impact of altered plasma protein binding, a common issue in frail or malnourished older patients. You will analyze a scenario where a decrease in plasma albumin changes the unbound fraction ($f_u$) of a highly protein-bound drug. This problem will challenge you to think beyond total drug concentration and focus on the pharmacologically active unbound concentration, a crucial step in optimizing therapy and avoiding toxicity [@problem_id:4953367].", "problem": "A 78-year-old patient with epilepsy is maintained on a constant-rate oral regimen of valproate that achieves a measured average total steady-state concentration of $60$ $\\mathrm{mg}\\,\\mathrm{L}^{-1}$ under stable conditions. At baseline, the unbound (free) fraction $f_u$ is $0.10$, and the therapeutic goal is to maintain the same unbound steady-state concentration that was present at baseline. Several weeks later, serum albumin falls due to malnutrition, and $f_u$ doubles to $0.20$. Assume the following are true over the concentration range of interest: valproate exhibits linear binding in plasma, it is a low hepatic extraction drug, intrinsic metabolic capacity is unchanged, hepatic blood flow is unchanged, and no autoinduction or inhibition occurs. Using only steady-state mass balance and binding principles applicable to low-extraction, highly protein-bound drugs, determine the multiplicative dose adjustment factor required to maintain the target unbound steady-state concentration after $f_u$ doubles. Then, determine the ratio of the new to old total steady-state concentrations under that dose adjustment. Express your final answer as a two-entry row matrix $\\begin{pmatrix}\\text{dose adjustment factor} & \\text{new/old total concentration}\\end{pmatrix}$, both dimensionless numbers. Provide exact values; do not round. Do not include units in the final boxed answer.", "solution": "The problem statement has been analyzed and is deemed valid. It is a scientifically sound, well-posed problem in clinical pharmacokinetics that relies on established principles of steady-state mass balance and protein binding.\n\nLet the initial state be denoted by subscript $1$ and the final state (after the fall in serum albumin) by subscript $2$. The dosing rate, which is proportional to the dose, is denoted by $R_0$. The total steady-state plasma concentration is $C_{ss,tot}$, the unbound (free) steady-state plasma concentration is $C_{ss,u}$, the unbound fraction is $f_u$, the total systemic clearance is $CL_{tot}$, and the intrinsic metabolic clearance is $CL_{int}$.\n\nAt steady state, the rate of drug administration is equal to the rate of drug elimination:\n$$R_0 = CL_{tot} \\times C_{ss,tot}$$\nThe unbound concentration is related to the total concentration by the unbound fraction:\n$$C_{ss,u} = f_u \\times C_{ss,tot}$$\nCombining these two equations gives a relationship for the unbound concentration:\n$$C_{ss,u} = f_u \\times \\frac{R_0}{CL_{tot}}$$\n\nThe problem specifies that valproate is a low hepatic extraction drug. For such drugs, the total systemic clearance ($CL_{tot}$), assuming it is dominated by hepatic clearance, is not limited by hepatic blood flow ($Q_H$) but is instead dependent on the intrinsic metabolic capacity of the liver enzymes ($CL_{int}$) and the fraction of drug that is unbound and available for metabolism ($f_u$). The relationship is given by:\n$$CL_{tot} \\approx f_u \\times CL_{int}$$\nThis approximation is valid for low extraction ratio drugs where $f_u \\cdot CL_{int} \\ll Q_H$.\n\nSubstituting this expression for clearance into the equation for unbound steady-state concentration yields a crucial result:\n$$C_{ss,u} = f_u \\times \\frac{R_0}{f_u \\times CL_{int}} = \\frac{R_0}{CL_{int}}$$\nThis equation shows that for a low-extraction drug with constant intrinsic clearance, the unbound steady-state concentration is directly proportional to the dosing rate and is independent of changes in protein binding (i.e., independent of $f_u$).\n\nThe therapeutic goal is to maintain the same unbound concentration that was present at baseline. Thus, we must have $C_{ss,u,2} = C_{ss,u,1}$.\nUsing the derived relationship:\n$$C_{ss,u,1} = \\frac{R_{0,1}}{CL_{int,1}}$$\n$$C_{ss,u,2} = \\frac{R_{0,2}}{CL_{int,2}}$$\nThe problem states that the intrinsic metabolic capacity is unchanged, so $CL_{int,1} = CL_{int,2} = CL_{int}$. To maintain $C_{ss,u,2} = C_{ss,u,1}$, we must therefore have:\n$$\\frac{R_{0,2}}{CL_{int}} = \\frac{R_{0,1}}{CL_{int}}$$\nThis implies $R_{0,2} = R_{0,1}$. The dose adjustment factor is the ratio of the new dosing rate to the old dosing rate, $\\frac{R_{0,2}}{R_{0,1}}$.\n$$\\text{Dose adjustment factor} = \\frac{R_{0,2}}{R_{0,1}} = 1$$\nThis means that no change in the dose is required to maintain the target unbound drug concentration.\n\nNext, we must determine the ratio of the new total steady-state concentration ($C_{ss,tot,2}$) to the old total steady-state concentration ($C_{ss,tot,1}$).\nThe total concentration is given by $C_{ss,tot} = \\frac{R_0}{CL_{tot}} = \\frac{R_0}{f_u \\cdot CL_{int}}$.\nThe initial total concentration is:\n$$C_{ss,tot,1} = \\frac{R_{0,1}}{f_{u,1} \\cdot CL_{int}}$$\nThe new total concentration, under the dose adjustment determined above (which was no adjustment, so $R_{0,2} = R_{0,1}$), is:\n$$C_{ss,tot,2} = \\frac{R_{0,2}}{f_{u,2} \\cdot CL_{int}} = \\frac{R_{0,1}}{f_{u,2} \\cdot CL_{int}}$$\nThe ratio of the new to old total concentrations is:\n$$\\frac{C_{ss,tot,2}}{C_{ss,tot,1}} = \\frac{\\frac{R_{0,1}}{f_{u,2} \\cdot CL_{int}}}{\\frac{R_{0,1}}{f_{u,1} \\cdot CL_{int}}}$$\nCanceling the common terms $R_{0,1}$ and $CL_{int}$, we get:\n$$\\frac{C_{ss,tot,2}}{C_{ss,tot,1}} = \\frac{f_{u,1}}{f_{u,2}}$$\nThe problem provides the values for the unbound fractions: $f_{u,1} = 0.10$ and $f_{u,2} = 0.20$. Substituting these values:\n$$\\frac{C_{ss,tot,2}}{C_{ss,tot,1}} = \\frac{0.10}{0.20} = \\frac{1}{2} = 0.5$$\nThus, although the therapeutically active unbound concentration remains the same, the new measured total concentration will be half of the original value. Specifically, the new total concentration will be $0.5 \\times 60 \\, \\mathrm{mg}\\,\\mathrm{L}^{-1} = 30 \\, \\mathrm{mg}\\,\\mathrm{L}^{-1}$.\n\nThe two required values are the dose adjustment factor ($1$) and the ratio of new to old total concentration ($0.5$).", "answer": "$$\\boxed{\\begin{pmatrix}1 & 0.5\\end{pmatrix}}$$", "id": "4953367"}]}